Skip to content
MARKETS / NASDAQ / TKNO
NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · SMALL CAP

Alpha Teknova, Inc. TKNO

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$40.5M
▲ 7.4% YoY
$-17.3M
$-9.8M
In brief

What this company does

The company offers three primary product types: pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. As of December 31, 2025, the company had 158 employees, all of which were full-time, including 88 employees in its operations organization, 45 in administrative functions, 15 in sales and marketing and 10 in engineering and research and development. None of the company's employees are represented by a labor union or are subject to a collective bargaining agreement. The company's headquarters are located in Hollister, California, where it leases approximately 190,000 square feet of commercial, office, manufacturing, and warehouse space at five separate locations in the same vicinity, referred to collectively as its Hollister campus.

Written from the business description in Alpha Teknova, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 2 March 2026. Every sentence was checked against that document before publication.

Growth
USD 40.5M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 40.5 · Net income -17.3
20M40M-20M-40M202020212022202320242025
Compound annual growth
−0.7%
+5.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +5.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−43 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -41.9% · Net -42.6%
5%10%-50%-100%202020212022202320242025
ROE
FY2025 · ROE -22.8%
10%20%-10%-20%-30%202020212022202320242025

Each USD of equity lost 23 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -9.8
-20M-40M202020212022202320242025

Total assetsUSD 103.6M
EquityUSD 68.8M
CashUSD 5.9M
Gross debtUSD 13.1M
Net debtUSD 7.2M
Current ratio4.58×

Net debt stands at 10% of equity.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020
Revenue $B0.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.00.0
EBITDA $B−0.0−0.0−0.0−0.0−0.00.0
Income tax $B0.0−0.0−0.0−0.0−0.00.0
Net income $B−0.0−0.0−0.0−0.0−0.00.0
Free cash flow $B−0.0−0.0−0.0−0.1−0.0−0.0
EPS, diluted $−0.32−0.57−1.16−1.69−0.610.16
Dividend / sh $······
Payout %······
ROE %−22.8−31.0−38.7−39.1−12.321.3
Shares out B0.050.050.040.030.030.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 30 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 65 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityIn Vitro & In Vivo Diagnostic Substances
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2020

Share this section

Download image